Grafts (+24%), patches (+13%) and carotid shunts (+18%) drove Q3 sales growth ... respectively. Chairman/CEO George LeMaitre said, “2024 is shaping up to be a year of healthy sales and profit growth.

LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the ...

Lemaitre Vascular ( (LMAT)) has released its ... This growth was driven by strong sales in grafts, patches, and carotid shunts. The company also saw impressive regional sales increases, with ...

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Lemaitre Vascular (LMAT ... increases in their grafts, carotid shunts, and patches segments.

LeMaitre Vascular Inc (NASDAQ:LMAT) reported a strong 16% sales growth in Q3 2024, driven by significant increases in grafts, patches, and carotid shunts. The company achieved a 49% EPS growth ...

LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the ...

and carotid shunts (+18%) d BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2024 financial results ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq ... Grafts (+24%), patches (+13%) and carotid shunts (+18%) drove Q3 sales growth. APAC sales increased 24%, EMEA 22% and the Americas 12%.

LeMaitre Vascular Inc (NASDAQ:LMAT) reported a strong 16% sales growth in Q3 2024, driven by significant increases in grafts, patches, and carotid shunts. The company achieved a 49% EPS growth, ...

Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided ...